ACHILLION PHARMACEUTICALS IN's ticker is ACHN and the CUSIP is 00448Q201. A total of 124 filers reported holding ACHILLION PHARMACEUTICALS IN in Q2 2018. The put-call ratio across all filers is 0.37 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2019 | $169,000 | -82.8% | 28,005 | -89.7% | 0.00% | -88.9% |
Q3 2019 | $981,000 | +178.7% | 272,465 | +107.7% | 0.01% | +200.0% |
Q2 2019 | $352,000 | +186.2% | 131,168 | +216.8% | 0.00% | +200.0% |
Q1 2019 | $123,000 | +48.2% | 41,407 | -20.9% | 0.00% | 0.0% |
Q4 2018 | $83,000 | -93.9% | 52,328 | -85.9% | 0.00% | -93.8% |
Q3 2018 | $1,368,000 | +117.1% | 371,657 | +66.9% | 0.02% | +100.0% |
Q2 2018 | $630,000 | -5.8% | 222,685 | -4.1% | 0.01% | -33.3% |
Q4 2017 | $669,000 | +208.3% | 232,146 | +381.1% | 0.01% | +200.0% |
Q3 2017 | $217,000 | -11.4% | 48,251 | -17.2% | 0.00% | -42.9% |
Q1 2017 | $245,000 | -61.2% | 58,268 | -61.9% | 0.01% | -73.1% |
Q4 2016 | $631,000 | +122.2% | 152,825 | +336.6% | 0.03% | +36.8% |
Q3 2016 | $284,000 | -35.5% | 35,000 | -37.9% | 0.02% | -29.6% |
Q2 2016 | $440,000 | +95.6% | 56,400 | +93.8% | 0.03% | +58.8% |
Q1 2016 | $225,000 | -70.5% | 29,100 | -58.9% | 0.02% | -79.8% |
Q4 2015 | $764,000 | – | 70,800 | – | 0.08% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RA Capital Management | 13,633,220 | $56,305,000 | 7.98% |
BVF INC/IL | 2,423,300 | $10,008,000 | 2.01% |
EMORY UNIVERSITY | 454,102 | $1,875,000 | 1.85% |
DAFNA Capital Management LLC | 196,500 | $812,000 | 0.71% |
Orbimed Advisors | 13,107,200 | $54,133,000 | 0.69% |
RTW INVESTMENTS, LP | 286,285 | $1,182,000 | 0.44% |
Marcus Capital, LLC | 100,000 | $413,000 | 0.44% |
Rock Springs Capital Management LP | 1,375,000 | $5,679,000 | 0.38% |
Spark Investment Management LLC | 978,600 | $4,041,000 | 0.33% |
Bellevue Group AG | 240,000 | $991,000 | 0.20% |